Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.09
- Piotroski Score 3.00
- Grade Buy
- Symbol (URGN)
- Company UroGen Pharma Ltd.
- Price $11.19
- Changes Percentage (-5.65%)
- Change -$0.67
- Day Low $11.16
- Day High $11.95
- Year High $20.70
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $40.00
- High Stock Price Target $60.00
- Low Stock Price Target $22.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.22
- Trailing P/E Ratio -4.1
- Forward P/E Ratio -4.1
- P/E Growth -4.1
- Net Income $-102,244,000
Income Statement
Quarterly
Annual
Latest News of URGN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now
A recent analysis ranks UroGen Pharma against the worst Middle East and Africa stocks according to short sellers. Despite challenges, the MENA region shows growth potential, with UroGen Pharma aiming ...
By Yahoo! Finance | 1 month ago -
UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock
The article discusses the impact of ADR stocks on foreign companies, particularly UroGen Pharma (NASDAQ:URGN), in the U.S. market. Despite challenges, ADRs facilitate investment opportunities for Amer...
By Yahoo! Finance | 1 month ago
